PPT-CLINICAL EXPERIENCE OF NSCLC in RSDM

Ana Rima PENDAHULUAN 2 Kanker Paru P enyebab utama kematian akibat kanker Terdiagnosis pada stadium lanjut Pembagian pasien kanker paru berdasarkan stadium di bangsal paru RSDM Th 2014 . Brada. . Torino. . 6 March 2015. Perspectives in lung cancer. . Stereotactic ablative radiation therapy (. SABR). in patients with inoperable NSCLC. SABR in the context of modern radiotherapy of . Gandara. , MD. University of California, Davis . Comprehensive Cancer Center. Biomarker-driven Phase III Clinical Trials: . Practical . & . Design Considerations. Clinical trial . d. esigns that define the. Nathan Pennell, M.D., Ph.D.. September 6, 2014. Objectives. Discuss the role of chemotherapy in molecularly defined populations. Discuss the addition of chemo and/or bevacizumab (Avastin) to targeted therapy. Renato G. Martins, MD, MPH. Medical Director, Thoracic/Head and Neck; General Oncology and Hematology. Seattle Cancer Care Alliance. July 28, 2015. 11:30 am – 12:30 pm, EST. ICLIO e-Course 02. Objectives. of the expression of . 17-beta-hydroxysteroid . dehydrogenases. . type 1 and type 2 . in non-small cell lung cancer. Paweł Jagodziński. Hanna . Drzewiecka. ; M.Sc.. Ph. . D. student. Department of . Jared Weiss, MD . Assistant . Professor of Medicine . Division . of Hematology and Oncology . University . of North Carolina School of Medicine . Attending Physician. UNC . Lineberger. Comprehensive Cancer . Hofstra North Shore-LIJ School of Medicine. Curriculum Committee Presentation. October 22, 2012. Transitions. Spring . Break: 3/25 – 4/1/13. Comprehensive Basic Science Test: 4/2 – 4/5. Step 1 Study Time: 4/6– 5/31/13. The Coming Paradigm Shift. Faculty. Suresh S. Ramalingam, MD. Professor of Hematology/Oncology . Director, Lung . Cancer Program . Winship Cancer Institute. Emory University. Atlanta, . Georgia. Program Goals. The Cancer genome atlas (TCGA) and the search for a CUP genetic/epigenetic signature Manel Esteller , MD, PhD. Director, Josep Carreras Leukaemia Research Institute (IJC) Director, Cancer Epigenetics and Biology Program (PEBC) proceedings from the live CME event and may include . the use of trade names and other raw, unedited content. . Moderator. Neil Love, MD. Faculty . Oncology Grand Rounds. . Emerging Strategies in Non-Small Cell Lung Cancer. Abramson Cancer Center . University of Pennsylvania. Philadelphia, Pennsylvania. Keeping Up in NSCLC: Actionable Biomarkers and Their Impact on Treatment. Rasheda Persinger, MSN, AGNP-C, AOCNP. Lead Nurse Practitioner. . 5. th. most commonly diagnosed cancer in Australia. 8.9% of new cancer diagnoses. In 2009: . 10,193 cases (. 6034 . men, 4159 women). Projection to . 2020.  . 13,640. Mortality. In 2010 most common cause of cancer death. Clinical . Skills Simulation Centre. Space. . 3 floors . 91 skills rooms/clinics. 5000 m. 2. B-Line Medical video capture system . Obstetrics, Pediatrics, & Adult wards. ER & OR simulation. Procedural skills laboratories. Intervista a Federico . Cappuzzo. Background:. Programmed death-ligand 1 (PD-L1) expression on tumor cells (TC) or tumor-infiltrating immune cells (IC) is associated with OS, PFS and ORR in pts with advanced NSCLC treated with atezolizumab (anti-PDL1, MPDL3280A; Spigel et al, Spira et al, ASCO 2015), indicating that PD-L1 expression on both TC and IC is important for anti-tumor immunity. However, these 2 distinct expression patterns suggest the existence of previously unidentified NSCLC subtypes with distinct immunologic profiles. .